AYHAM AL ASHKAR MD NPI 1417084799

NPI Details

Ayham Al Ashkar, MD is a medical oncology internal medicine in Royal Oak, MI with 28 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Ayham Al Ashkar, MD NPI is 1417084799. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

3577 W 13 RD # 310
ROYAL OAK, MI
ZIP 48073
Phone: (248) 551-2446
Fax: (248) 551-1094

The NPI 1417084799 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, octreotide, depot form for intramuscular injection, 1 mg (HCPCS:J2353)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Blood test, basic group of blood chemicals (calcium, ionized) (HCPCS:80047)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Unclassified drugs (HCPCS:J3490)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Injection of drug or substance into vein (HCPCS:96374)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Drawing of blood for a medical problem (HCPCS:99195)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)

The enumeration date for this NPI number is 2/27/2007 and was last updated on 7/5/2023.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: